title: Correlation of C4ST-1 and ChGn-2 expression with chondroitin sulfate chain elongation in atherosclerosis.
abstract: Subendothelial retention of lipoproteins by proteoglycans (PGs) is the initiating event in atherosclerosis. The elongation of chondroitin sulfate (CS) chains is associated with increased low-density lipoprotein (LDL) binding and progression of atherosclerosis. Recently, it has been shown that 2 Golgi enzymes, chondroitin 4-O-sulfotransferase-1 (C4ST-1) and chondroitin N-acetylgalactosaminyltransferase-2 (ChGn-2), play a critical role in CS chain elongation. However, the roles of C4ST-1 and ChGn-2 during the progression of atherosclerosis are not known. The aim of this study was to analyze the expression of C4ST-1 and ChGn-2 in atherosclerotic lesions in vivo and determine whether their expression correlated with CS chain elongation. Low-density lipoprotein receptor knockout (LDLr KO) mice were fed a western diet for 2, 4, and 8weeks to stimulate development of atherosclerosis. The binding of LDL and CS PG in this mouse model was confirmed by chondroitinase ABC (ChABC) digestion and apolipoprotein B (apo B) staining. Gel filtration analysis revealed that the CS chains began to elongate as early as 2weeks after beginning a western diet and continued as the atherosclerosis progressed. Furthermore, quantitative real-time polymerase chain reaction (qRT-PCR) showed that the mRNA levels of C4ST-1 and ChGn-2 increased after 8weeks of this diet. In contrast, the mRNA levels of their homologs, C4ST-2 and ChGn-1, were unchanged. In addition, immunohistochemical analysis demonstrated that the expression of C4ST-1 and ChGn-2 appeared to have similar site-specific patterns and coincided with biglycan expression at the aortic root. Our results suggested that C4ST-1 and ChGn-2 may be involved in the elongation of CS chains in the arterial wall during the progression of atherosclerosis. Therefore, modulating their expression and activity might be a novel therapeutic strategy for atherosclerosis.
authors.affiliation: Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
authors.forename: Vita Yanti
authors.initials: VY
authors.lastname: Anggraeni
authors.forename: Noriaki
authors.initials: N
authors.lastname: Emoto
authors.forename: Keiko
authors.initials: K
authors.lastname: Yagi
authors.forename: Dyah Samti
authors.initials: DS
authors.lastname: Mayasari
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Nakayama
authors.forename: Tomomi
authors.initials: T
authors.lastname: Izumikawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kitagawa
authors.forename: Ken-ichi
authors.initials: K
authors.lastname: Hirata
mesh_terms: D000818:Animals; D001011:Aorta / Q000378:metabolism / Q000473:pathology; D050197:Atherosclerosis / Q000378:metabolism* / Q000473:pathology; D058578:Biglycan / Q000378:metabolism; D002809:Chondroitin Sulfates / Q000378:metabolism*; D008077:Lipoproteins, LDL / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D017350:N-Acetylgalactosaminyltransferases / Q000096:biosynthesis* / Q000235:genetics; D011973:Receptors, LDL / Q000235:genetics; D015238:Sulfotransferases / Q000096:biosynthesis* / Q000235:genetics; D000097811:Carbohydrate Sulfotransferases
chemical_list: D058578:Biglycan; D002809:Chondroitin Sulfates; D008077:Lipoproteins, LDL; D017350:N-Acetylgalactosaminyltransferases; D011973:Receptors, LDL; D015238:Sulfotransferases; C472560:chondroitin sulfate N-acetylgalactosaminyltransferase-2; C557901:Chst11 protein, mouse; D000097811:Carbohydrate Sulfotransferases